Who are CancerVax vaccine (CANVAXIN)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): VEC, CPA, D-cure, GC3110B vaccine, HAPREP®, MR-Vac.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cancervax-vaccine-canvaxin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

CancerVax vaccine (CANVAXIN) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CancerVax vaccine (CANVAXIN) (CancerVax vaccine (CANVAXIN)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Therapeutic cancer vaccine. Area: Oncology.

phase 3 Therapeutic cancer vaccine MAGE-1, MAGE-3 (melanoma-associated antigens) Oncology Biologic Live · refreshed every 30 min

Target snapshot

CancerVax vaccine (CANVAXIN) (CancerVax vaccine (CANVAXIN)) — CancerVax Corporation. CANVAXIN is a therapeutic cancer vaccine that stimulates the immune system to recognize and attack cancer cells expressing specific tumor-associated antigens.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
CancerVax vaccine (CANVAXIN) TARGET	CancerVax vaccine (CANVAXIN)	CancerVax Corporation	phase 3	Therapeutic cancer vaccine	MAGE-1, MAGE-3 (melanoma-associated antigens)
VEC	VEC	Centre Leon Berard	marketed	Therapeutic cancer vaccine
CPA	CPA	ImmunoVaccine Technologies, Inc. (IMV Inc.)	marketed	Therapeutic cancer vaccine
D-cure	D-cure	KU Leuven	marketed	Therapeutic cancer vaccine
GC3110B vaccine	GC3110B vaccine	Green Cross Corporation	phase 3	Therapeutic cancer vaccine
HAPREP®	HAPREP®	National Cancer Center, Korea	phase 3	Therapeutic cancer vaccine	Patient-specific tumor neoantigens
MR-Vac	MR-Vac	GlaxoSmithKline	phase 3	Therapeutic cancer vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Therapeutic cancer vaccine class)

GlaxoSmithKline · 2 drugs in this class
Green Cross Corporation · 2 drugs in this class
Chiang Mai University · 1 drug in this class
Chiltern Pesquisa Clinica Ltda · 1 drug in this class
GERCOR - Multidisciplinary Oncology Cooperative Group · 1 drug in this class
Galena Biopharma, Inc. · 1 drug in this class
Genocea Biosciences, Inc. · 1 drug in this class
ImmunoVaccine Technologies, Inc. (IMV Inc.) · 1 drug in this class
Istituto Oncologico Veneto IRCCS · 1 drug in this class
KU Leuven · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CancerVax vaccine (CANVAXIN) — Competitive Intelligence Brief. https://druglandscape.com/ci/cancervax-vaccine-canvaxin. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab